Shanghai RAAS Blood Products
Shanghai RAAS Blood Products Co Ltd is a Chinese biopharmaceutical enterprise specializing in plasma-derived biopharmaceutical products. The company operates plasma collection stations and manufactures human albumin, intravenous immunoglobulin, human coagulation factor VIII, and fibrinogen therapies. Main revenue drivers consist of domestic sales of plasma-based therapeutics to hospitals and medical institutions for emergency and immunological treatment. Shanghai RAAS Blood Products serves clinical hospitals, medical research facilities, and critical care patients across mainland China. The company occupies a market-leading position as one of the largest plasma biopharmaceutical producers in China's domestic healthcare market. Headquartered in Shanghai, China, the company is listed on the Shenzhen Stock Exchange.
4 of the funds FundTelligence covers report a position in Shanghai RAAS Blood Products.
- Legal name
- Shanghai RAAS Blood Products Co. Ltd.
- Sector
- Health Care
- Country
- China
- Funds holding it
- 4
Funds holding Shanghai RAAS Blood Products
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.01 % (full portfolio disclosed, July 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.0 % (full portfolio disclosed, June 2026)